Big Law
Angelini Pharma to Acquire US-Based Catalyst Pharmaceuticals in $4.1 Billion Deal
Italian pharmaceutical group Angelini Pharma has agreed to acquire US-based Catalyst Pharmaceuticals in a cash deal worth about $4.1bn.
The company said the transaction marks its entry into the US market and expands its presence in Brain Health and Rare Diseases.
Under the definitive agreement, Angelini Pharma will buy all outstanding shares of Catalyst Pharmaceuticals for $31.50 per share in cash.
Read more at Investment Monitor
